Literature DB >> 23773419

The spatial distribution of atrial fibrillation termination sites in the right atrium during complex fractionated atrial electrograms-guided ablation in patients with persistent atrial fibrillation.

Yung-Lung Chen1, Ji-Eun Ban, Yae-Min Park, Jong-Il Choi, Sang-Weon Park, Young-Hoon Kim.   

Abstract

BACKGROUND: The role of right atrial (RA) ablation guided by complex fractionated atrial electrograms (CFAE) in atrial fibrillation (AF) has been debated. This study evaluated the spatial distribution of RA CFAE, the critical sites, and the predictors of successful termination of longstanding persistent AF during RA ablation.
METHODS: A total of 97 patients with persistent AF who received automated detection of CFAE mapping and ablation at the RA for sustained AF after pulmonary vein isolation and left atrial (LA) CFAE-guided ablation were analyzed. The AF termination patterns and CFAE areas were analyzed.
RESULTS: Forty-eight (49%) patients successfully converted to atrial tachycardia (AT) or sinus rhythm (SR) during CFAE-guided ablation at the RA. Of these, 7 (15%) patients converted directly to SR, and 41 (85%) converted via AT. The crista terminalis (CT) was the most common site for AT conversion during RA CFAE ablation, followed by the RA appendage and RA septum. Patients with larger RA volumes (> 145 mm3) had lower rates of SR or AT conversion during RA CFAE ablation. Patients with AF termination during RA CFAE ablation had less late recurrence than those without AF termination (P = 0.003).
CONCLUSION: A half of patients with persistent AF refractory to LA ablation successfully converted to AT or SR during automated CFAE-guided ablation at the RA. The most common critical sites for AF termination were the CT and RA appendage and septum. Patients with AF termination during procedure whether LA CFAE only or after RA CFAE ablation had better outcome with less late recurrence of atrial tachyarrhythmia compared to those without AF termination.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial fibrillation; catheter ablation; complex fractionated atrial electrograms; pulmonary vein isolation; right atrium; spatial distribution

Mesh:

Year:  2013        PMID: 23773419     DOI: 10.1111/jce.12187

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  5 in total

1.  Atrial Substrate Modification in Atrial Fibrillation: Targeting GP or CFAE? Evidence from Meta-Analysis of Clinical Trials.

Authors:  Mu Qin; Xu Liu; Shao-Hui Wu; Xiao-Dong Zhang
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

2.  Does Additional Electrogram-Guided Ablation After Linear Ablation Reduce Recurrence After Catheter Ablation for Longstanding Persistent Atrial Fibrillation? A Prospective Randomized Study.

Authors:  Tae-Hoon Kim; Jae-Sun Uhm; Jong-Youn Kim; Boyoung Joung; Moon-Hyoung Lee; Hui-Nam Pak
Journal:  J Am Heart Assoc       Date:  2017-02-07       Impact factor: 5.501

3.  Low-Dose Ibutilide Combined with Catheter Ablation of Persistent Atrial Fibrillation: Procedural Impact and Clinical Outcome.

Authors:  Xue-Rong Sun; Ying Tian; Ashok Shah; Xian-Dong Yin; Liang Shi; Yan-Jiang Wang; Xiao-Qing Liu; Meleze Hocini; Michel Haissaguerre; Xin-Chun Yang; Xing-Peng Liu
Journal:  Cardiol Res Pract       Date:  2019-01-02       Impact factor: 1.866

4.  Left atrial posterior wall isolation affects complex fractionated atrial electrograms in persistent atrial fibrillation.

Authors:  Yosuke Nakatani; Tamotsu Sakamoto; Yoshiaki Yamaguchi; Yasushi Tsujino; Naoya Kataoka; Kunihiro Nishida; Koichi Mizumaki; Koichiro Kinugawa
Journal:  J Arrhythm       Date:  2019-04-12

5.  Association of right atrial structure with incident atrial fibrillation: a longitudinal cohort cardiovascular magnetic resonance study from the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Eric Xie; Ricky Yu; Bharath Ambale-Venkatesh; Hooman Bakhshi; Susan R Heckbert; Elsayed Z Soliman; David A Bluemke; Steven M Kawut; Colin O Wu; Saman Nazarian; João A C Lima
Journal:  J Cardiovasc Magn Reson       Date:  2020-05-21       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.